Cargando…
Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smoke...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401386/ https://www.ncbi.nlm.nih.gov/pubmed/28431499 http://dx.doi.org/10.1186/s12890-017-0414-6 |
_version_ | 1783231037088727040 |
---|---|
author | Montes de Oca, Maria Victorina Lopez Varela, Maria Laucho-Contreras, Maria E. Casas, Alejandro Schiavi, Eduardo Mora, Juan Carlos |
author_facet | Montes de Oca, Maria Victorina Lopez Varela, Maria Laucho-Contreras, Maria E. Casas, Alejandro Schiavi, Eduardo Mora, Juan Carlos |
author_sort | Montes de Oca, Maria |
collection | PubMed |
description | BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smokers and/or exposed to biomass, attending routine primary care visits completed a questionnaire and performed spirometry. COPD was defined as post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) < 0.70; asthma was defined as either prior asthma diagnosis or wheezing in the last 12 months plus reversibility (increase in post-bronchodilator FEV(1) or FVC ≥200 mL and ≥12%); ACOS was defined using a combination of COPD with the two asthma definitions. Exacerbations in the past year among the subgroups were evaluated. RESULTS: One thousand seven hundred forty three individuals completed the questionnaire, 1540 performed acceptable spirometry, 309 had COPD, 231 had prior asthma diagnosis, and 78 asthma by wheezing + reversibility. ACOS prevalence in the total population (by post-bronchodilator FEV(1)/FVC < 0.70 plus asthma diagnosis) was 5.3 and 2.3% by post-bronchodilator FEV(1)/FVC < 0.70 plus wheezing + reversibility. In the obstructive population (asthma or COPD), prevalence rises to 17.9 and 9.9% by each definition, and to 26.5 and 11.3% in the COPD population. ACOS patients defined by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility had the lowest lung function measurements. Exacerbations for ACOS showed a prevalence ratio of 2.68 and 2.20 (crude and adjusted, p < 0.05, respectively) (reference COPD). CONCLUSIONS: ACOS prevalence in primary care varied according to definition used. ACOS by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility represents a clinical phenotype with more frequent exacerbations, which is probably associated with a different management approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-017-0414-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5401386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54013862017-04-24 Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study Montes de Oca, Maria Victorina Lopez Varela, Maria Laucho-Contreras, Maria E. Casas, Alejandro Schiavi, Eduardo Mora, Juan Carlos BMC Pulm Med Research Article BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smokers and/or exposed to biomass, attending routine primary care visits completed a questionnaire and performed spirometry. COPD was defined as post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) < 0.70; asthma was defined as either prior asthma diagnosis or wheezing in the last 12 months plus reversibility (increase in post-bronchodilator FEV(1) or FVC ≥200 mL and ≥12%); ACOS was defined using a combination of COPD with the two asthma definitions. Exacerbations in the past year among the subgroups were evaluated. RESULTS: One thousand seven hundred forty three individuals completed the questionnaire, 1540 performed acceptable spirometry, 309 had COPD, 231 had prior asthma diagnosis, and 78 asthma by wheezing + reversibility. ACOS prevalence in the total population (by post-bronchodilator FEV(1)/FVC < 0.70 plus asthma diagnosis) was 5.3 and 2.3% by post-bronchodilator FEV(1)/FVC < 0.70 plus wheezing + reversibility. In the obstructive population (asthma or COPD), prevalence rises to 17.9 and 9.9% by each definition, and to 26.5 and 11.3% in the COPD population. ACOS patients defined by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility had the lowest lung function measurements. Exacerbations for ACOS showed a prevalence ratio of 2.68 and 2.20 (crude and adjusted, p < 0.05, respectively) (reference COPD). CONCLUSIONS: ACOS prevalence in primary care varied according to definition used. ACOS by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility represents a clinical phenotype with more frequent exacerbations, which is probably associated with a different management approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-017-0414-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-21 /pmc/articles/PMC5401386/ /pubmed/28431499 http://dx.doi.org/10.1186/s12890-017-0414-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Montes de Oca, Maria Victorina Lopez Varela, Maria Laucho-Contreras, Maria E. Casas, Alejandro Schiavi, Eduardo Mora, Juan Carlos Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title | Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title_full | Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title_fullStr | Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title_full_unstemmed | Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title_short | Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study |
title_sort | asthma–copd overlap syndrome (acos) in primary care of four latin america countries: the puma study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401386/ https://www.ncbi.nlm.nih.gov/pubmed/28431499 http://dx.doi.org/10.1186/s12890-017-0414-6 |
work_keys_str_mv | AT montesdeocamaria asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy AT victorinalopezvarelamaria asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy AT lauchocontrerasmariae asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy AT casasalejandro asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy AT schiavieduardo asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy AT morajuancarlos asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy |